This is an early-stage regulatory milestone with no financial data — the stock has historically been highly volatile on news. Monitor for future development milestones, capital raises (the company's S-1/A filed August 20, 2026 suggests ongoing financing needs), and any progress toward clinical studies or Conditional Approval. The $3M market cap and pre-revenue status make this a high-risk binary event stock.
Price Chart
Executive Summary
Endovia Health Sciences (formerly Splash Beverage Group) announced that the FDA's Center for Veterinary Medicine has established Investigational New Animal Drug (INAD) File No. 14145 for its CannEpil veterinary development program, marking the first regulatory milestone under its collaboration with Lupvindol Biosciences. The program targets cancer-related pain in companion animals, beginning with canine oncology, and the company intends to pursue the FDA's Minor Use/Minor Species (MUMS) designation and Conditional Approval pathway. This is a non-financial, early-stage regulatory milestone with no revenue or earnings data provided, and the company remains a pre-revenue development-stage entity with a $3M market cap and a history of volatile stock movements.
Key Facts
- FDA established INAD File No. 14145 for CannEpil veterinary development program
- First regulatory milestone under collaboration agreement with Lupvindol Biosciences Ltd.
- Initially pursuing development for management of cancer-related pain in companion animals, beginning with canine oncology
- Company intends to pursue FDA's Minor Use / Minor Species (MUMS) designation and Conditional Approval pathway
- Company rebranded to Endovia Health Sciences (NYSE American: EDVA) effective August 24, 2026
- No financial data, revenue, earnings, or guidance provided in this filing
Financial Impact
No financial data provided in this filing; company is pre-revenue development-stage with $3M market cap
Risk Factors
- No revenue or earnings; company is pre-revenue development-stage
- Future capital needs likely given $3M market cap and development-stage status
- No guarantee of successful clinical studies or FDA Conditional Approval
- NYSE American continued listing standards risk mentioned in forward-looking statements
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001731122-26-001144 |
| Document: 0001731122-26-001144-index.html | 0001731122-26-001144 |
| Document: 0001731122-26-001144.txt | 0001731122-26-001144 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 7, 2026 18d ago | DEFA14A | — | awaiting T+5 | — | — |
Aug 25, 2026 8w ago | 8-K | $0.4715 | awaiting T+5 | — | — |
Aug 21, 2026 9w ago | 8-K | $0.4376 | awaiting T+5 | — | — |
Aug 20, 2026 9w ago | 8-K | $0.4250 | awaiting T+5 | — | — |
Aug 12, 2026 10w ago | 8-K | $0.4096 $0.4104 | ▲ +0.20% | ▲ +0.64% | — |
Aug 7, 2026 11w ago | S-1 | $0.4122 $0.3780 | ▲ +8.30% | ▲ +8.25% | — |
Aug 5, 2026 11w ago | 8-K | $0.4250 $0.4096 | ▼ −3.62% | ▼ −3.97% | — |
Jul 14, 2026 14w ago | 8-K | $0.1043 $0.0936 | ▼ −10.26% | ▼ −9.79% | — |
Jul 9, 2026 15w ago | 8-K | $0.1653 $0.0936 | ▲ +43.38% | ▲ +43.24% | — |
Jul 6, 2026 16w ago | 8-K | $0.2081 $0.1240 | ▼ −40.41% | ▼ −40.13% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers